
RH1
CAS No. 221635-42-3
RH1( —— )
Catalog No. M33479 CAS No. 221635-42-3
RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 299 | Get Quote |
![]() ![]() |
5MG | 424 | Get Quote |
![]() ![]() |
10MG | 682 | Get Quote |
![]() ![]() |
25MG | 1334 | Get Quote |
![]() ![]() |
50MG | 1822 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRH1
-
NoteResearch use only, not for human use.
-
Brief DescriptionRH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
-
DescriptionRH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number221635-42-3
-
Formula Weight234.25
-
Molecular FormulaC12H14N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C(=C(C(=O)C(=C1C)N2CC2)CO)N3CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
4-Thiothymidine
4-Thiothymidine is a Nucleoside Derivative - Thio-nucleoside, 5-Modified pyrimidine nucleoside.
-
Flavokawain B
Flavokawain B is a natural chalcone that can induce apoptosis in androgen receptor-negative, hormone-refractory prostate cancer cell lines (IC50=3-50 uM).
-
BFC1108
BFC1108 targets Bcl-2 and converts it to a pro-apoptotic protein, inhibits the growth of triple-negative breast cancer xenografts with high Bcl-2 expression, inhibits breast cancer lung metastasis, and induces apoptosis of Bcl-2-expressing cancer cells.